A Review on Gullian Barre Syndrome and its Association with COVID 19
Abstract
Guillain-Barré syndrome (GBS) is an immune-mediated disease that affects peripheral nerves and can lead to life-threatening consequences. It affects around 10000 people per year worldwide. Since the outbreak of acute respiratory syndrome coronavirus-2 (sar-cov-2) the incidence of GBS has been increased with a fatality rate of 4-7%. The exact association between the Sar-cov-2 and GBS is still unknown. GBS commonly presents after viral infections such as influenza virus, campylobacter jejuni, and zika virus. Clinical recognition of SC2-GBS is required in order to administer appropriate treatment on time and enhance the overall output of the infection. In most of the conditions patient was treated with intravenous immunoglobulins and outcome was seen within eight weeks of treatment. less outcome was seen in older age in line with previous findings for both GBS and COVID-19. Studies should be conducted to compare patients associated with GBS to those with concurrent non-COVID-19 GBS to see if the incidence of GBS is higher in those with COVID-19.
Keywords: Guillian-Barre syndrome, COVID-19, SAR-COV2
Keywords:
Guillian-Barre syndrome, COVID-19, SAR-COV2DOI
https://doi.org/10.22270/jddt.v11i6.5115References
Li X, Zai J, Zhao Q, et al., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020; 92(6):602-611. https://doi.org/10.1002/jmv.25731
WHO Director-General's opening remarks at the media briefing on COVID-19 (2020). Available online at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19 (accessed August 24, 2021).
Huang C, Wang Y, Li X, et al., Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Zhou P, Yang X-L, Wang X-G, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7
Mao L, Jin H, Wang M, et al., Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 IN WUHAN, CHINA. JAMA Neurol. 2020; 77(6):683. https://doi.org/10.1001/jamaneurol.2020.1127
Orlikowski D, Porcher R, Sivadon TV, et al., Guillain-Barre syndrome following Primary Cytomegalovirus Infection: A prospective cohort study. Clin. Infect. Dis. 2011; 52(7):837-844. https://doi.org/10.1093/cid/cir074
Wakerley BR, Yuki N. Infectious and non-infectious triggers in Guillain-Barre syndrome. Expert Rev. Clin. Immunol.2013;9:627-639. https://doi.org/10.1586/1744666X.2013.811119
Cao-Lormeau VM, Blake A, Mons S, et al., Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet.2016; 387(10027):1531-1539. https://doi.org/10.1016/S0140-6736(16)00562-6
Uncini A, González BDC, Acosta AYY, et al., Clinical and nerve conduction features in Guillain-Barre syndrome associated with Zika virus infection in Cúcuta, Colombia. Eur. J. Neurol.2018; 25:644-650. https://doi.org/10.1111/ene.13552
Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005; 366(9497):1653-1666. https://doi.org/10.1016/S0140-6736(05)67665-9
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology.2011; 36:123-133. https://doi.org/10.1159/000324710
Jacobs BC, Rothbarth PH, van der Meché FG, et al., The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology.1998; 51(4):1110-5. https://doi.org/10.1212/WNL.51.4.1110
Patanik UJ. Review article On COVID-19 and GUILLAIN-BARRÉ SYNDROME. Front. Biosci. 2021; 13(1):97. doi:10.52586/s555 https://doi.org/10.52586/S555
Nguyen TP, Taylor RS. Guillain Barre syndrome. 2021 July 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Jan-. [last accessed 17 August 2021] Available at https://www.ncbi.nlm.nih.gov/books/NBK532254/
Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients With covid-19. The Egypt. J. Neurol. Psychiatry Neurosurg. 2021; 57(1). https://doi.org/10.1186/s41983-021-00310-7
Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J. Neurol Neurosurg Psychiatry.2015; 86:1196-1201. https://doi.org/10.1136/jnnp-2014-309056
Filosto M, Cotti Piccinelli S, Gazzina S, et al., Guillain-Barré syndrome and COVID-19: An observational Multicentre study from two italian hotspot regions. J. Neurol. Neurosurg Psychiatry. 2020; 92(7):751-756. https://doi.org/10.1136/jnnp-2020-324837
van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré Syndrome. Lancet Neurol. 2008; 7(10):939-950. https://doi.org/10.1016/S1474-4422(08)70215-1
Parry GJ. Guillain-Barré Syndrome 42-55 (Thieme Medical Publishers, 1993).
Hughes RA. Guillain-Barré Syndrome 124-130 (Springer-Verlag, 1990). https://doi.org/10.1007/978-1-4471-3175-5
Ropper AH, Wijdicks EF, Truaxm BT. Guillain- Barré Syndrome 175-224 (F. A. Davis, 1991).
Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho NE. COVID-19 may induce Guillain-Barré syndrome. Rev Neurol.2020; 176(6): 516-518. https://doi.org/10.1016/j.neurol.2020.04.003
Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med. J. 2020; 97(1147):312-320. https://doi.org/10.1136/postgradmedj-2020-138577
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014; 137(1):33-43. https://doi.org/10.1093/brain/awt285
Devos D, Magot A, Perrier BJ, et al., Guillain-Barré syndrome during childhood: Particular clinical and electrophysiological features. Muscle Nerve. 2013; 48(2):247-251. https://doi.org/10.1002/mus.23749
Korinthenberg R, Schessl J, Kirschner J. Clinical Presentation and Course of Childhood Guillain-Barré Syndrome: A Prospective Multicentre Study. Neuropediatrics. 2007; 38(1):10-17. https://doi.org/10.1055/s-2007-981686
Roodbol J, Wit M, Walgaard C, Hoog M, Catsman BC, Jacobs B. Recognizing Guillain-Barre syndrome in preschool children. Neurology. 2011; 76(9):807-810. https://doi.org/10.1212/WNL.0b013e31820e7b62
Ryan MM. Guillain-Barré syndrome in childhood. J. Paediatr Child Health.2005; 41(5-6):237-241. https://doi.org/10.1111/j.1440-1754.2005.00602.x
Wit MC, Roodbol J, Hoog M, Catsman-B, Jacobs, BC. Imminent respiratory insufficiency in children resulting from Guillain-Barré syndrome [Dutch]. Nederlands Tijdschrift voor Geneeskunde.2011; 155:A3808.
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Revista de Neurologia.2020; 70(9):311-322. https://doi.org/10.33588/rn.7009.2020179
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck et.al., Neurologic features in severe SARSCoV-2 infection. N. Engl. J. Med. 2020; 382(23):2268-2270 https://doi.org/10.1056/NEJMc2008597
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J. clin. Neurosci.2020;76:233-239. https://doi.org/10.1016/j.jocn.2020.04.062
Bae JS, Kim YJ, Kim JK. Diabetes mellitus exacerbates the clinical and electrophysiological features of Guillain-Barré syndrome. Eur. J. Neurol. 2016; 23(3):439-46. https://doi.org/10.1111/ene.12885
Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol. Sci.2020; 41:3149-3156. https://doi.org/10.1007/s10072-020-04693-y
Martín-Aguilar L, Camps-Renom P, Lleixà C, Díaz-Manera J, Rojas-García R, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J. Neurol. Neurosurg. Psychiatry. 2021; 92:70-77. https://doi.org/10.1136/jnnp-2020-323899
Arcila-Londono X, Lewis RA. Guillain-Barré syndrome. Seminars in Neurology. 2020; 32(3):179-186. https://doi.org/10.1055/s-0032-1329196
Van den Berg, B.; Walgaard, C.; Drenthen, J.; Fokke, C.; Jacobs, B.C.; van Doorn, P.A. Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment, and prognosis. Nat. Rev. Neurol. 2014; 10(8):469-482. https://doi.org/10.1038/nrneurol.2014.121
Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with covid-19. Egypt. J. Neurol. Psychiatr. Neurosurg. 2021; 57(1) 1-7. https://doi.org/10.1186/s41983-021-00310-7
Andrea A, Luana B, Silvia DM, Erika S, Massimo DS. New clinical manifestation of COVID 19 related Guillain Barrè syndrome highly responsive to intravenous immunoglobulins: Two Italian cases. J. Neurol. Sci. 2020; 41:1657-1668. https://doi.org/10.1007/s10072-020-04484-5
Frontera J, Mainali S, Fink E et al. Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale. J. Neurocrit Care. 2020; 33(1):25-34. https://doi.org/10.1007/s12028-020-00995-3
Research C for BE and. Safety & Availability (Biologics) - FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. Accessed April 22, 2020. http://wayback.archiveit.org/7993/20170112095644/http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm37 5096.html
Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl. Stroke Res. 2020; 11(3):322- 325. https://doi.org/10.1007/s12975-020-00818-9
Hughes RAC, Swan AV, Raphaël J-C, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain.2007; 130(9):2245-2257. https://doi.org/10.1093/brain/awm004
Raphael, J. C., Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barré syndrome.Cochrane Database of Systematic Reviews. 2012; 7:CD001798. https://doi.org/10.1002/14651858.CD001798.pub2
[No authors listed] Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology.1985; 35(8);1096-1104. https://doi.org/10.1212/WNL.35.8.1096
[No authors listed] Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann. Neurol.1987; 22(6):753-761. https://doi.org/10.1002/ana.410220612
Hughes, R. A. & van Doorn, P. A. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews, Issue 8. Art. No.: CD001446.
Van Koningsveld R, Schmitz P, van der Meché F, Visser L, Meulstee J, van Doorn P. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004; 363(9404):192-196. https://doi.org/10.1016/S0140-6736(03)15324-X
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388(10045):717-27. https://doi.org/10.1016/S0140-6736(16)00339-1
Rodnitzky RL, Goeken JA. Complications of Plasma Exchange in Neurological Patients. Arch. Neurol. 1982; 39(6):350-354. https://doi.org/10.1001/archneur.1982.00510180028007
Jin PH, Shin SC, Dhamoon MS. Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: A case-crossover study. Muscle Nerve.2020:62(3); 327-332. https://doi.org/10.1002/mus.26884
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. J. Neurol. 2020; 268(4):1133-1170. https://doi.org/10.1007/s00415-020-10124-x
Winer JB. Treatment of Guillain-Barré syndrome. Monthly J. Assoc. Physicians. 2002; 95(11):717-721. https://doi.org/10.1093/qjmed/95.11.717
Gajjar, M D. et al. Efficacy and cost effectiveness of therapeutic plasma exchange in patient of Guillain-Barré syndrome-a prospective study. SEJCRR.2013; 2(4):218-228.
Winters JL., Brown D., Hazard E., Chainani A. Andrzejewski, C. Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Ser.Res. 2011; 11(1). https://doi.org/10.1186/1472-6963-11-101
van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013; 80(18):1650-1654. https://doi.org/10.1212/WNL.0b013e3182904fcc
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388(10045):717- 727. https://doi.org/10.1016/S0140-6736(16)00339-1
Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain-Barré syndrome: modern theories of etiology. Curr. Allergy. Asthma. Rep. 2011; 11(3):197-204. https://doi.org/10.1007/s11882-011-0190-y
Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, Guarrera GM, Giometto B. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol. Sci. 2020; 41(6):1351-1354. https://doi.org/10.1007/s10072-020-04449-8
Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, GonzálezManrique G, Vargas J, Angarita JA, Zuñiga G, Lopez-Gonzalez R, Beltran CL, Rizcala KH, Morales MT, Pacheco O, Ospina ML, Kumar A, Cornblath DR, Muñoz LS, Osorio L, Barreras P, Pardo CA. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 2016; 375(16):1513-1523 https://doi.org/10.1056/NEJMoa1605564
Finsterer J, Scorza FA, Ghosh R, COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid. J. Med. Virol. 2020; 93(1): 66-68. https://doi.org/10.1002/jmv.26121
Domingues R, Fernandes G, Leite F et al. The cerebrospinal fluid in multiple sclerosis: far beyond the bands. Einstein (São Paulo). 2017; 15(1):100-104. https://doi.org/10.1590/s1679-45082017rw3706
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388(10045):717-727. https://doi.org/10.1016/S0140-6736(16)00339-1
Walgaard C, Lingsma HF, Ruts L et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann. Neurol.2010; 67(6):781-787. https://doi.org/10.1002/ana.21976
van K R, Steyerberg E, Hughes R, Swan A, van D P, Jacobs B. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007; 6(7):589-594. https://doi.org/10.1016/S1474-4422(07)70130-8
Liu Y, Mao B, Liang S et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 2020; 55(5):2001112. https://doi.org/10.1183/13993003.01112-2020
Khanlou H, Valdes-Sueiras M, Farthing C. Peripheral Neuropathy Induced by Lopinavir-Saquinavir-Ritonavir Combination Therapy in an HIV-Infected Patient. J. Intern Ass. Physicians AIDS Care. 2007; 6(3):155-155. https://doi.org/10.1177/1545109707302756
Sugiura F, Kojima T, Oguchi T, Urata S, Yuzawa Y, Sakakibara A, et al. A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol. 2009; 19(2): 199-203. https://doi.org/10.3109/s10165-008-0132-2
Published
Abstract Display: 513 
PDF Downloads: 542 PDF Downloads: 24 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.